Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?

Precision BioSciences (DTIL) shares soared 13.4% in the last trading session to close at $15.37. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.6% gain over the past four weeks.

Last week, the company announced robust financial results for the fourth quarter and full-year ended 2023. This might have been driving the share price rally.

This genome editing company is expected to post quarterly loss of $1.80 per share in its upcoming report, which represents a year-over-year change of +74%. Revenues are expected to be $10.5 million, up 19.6% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For Precision BioSciences, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on DTIL going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Precision BioSciences belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, ChromaDex (CDXC), closed the last trading session 3.7% higher at $3.61. Over the past month, CDXC has returned 116.2%.

For ChromaDex, the consensus EPS estimate for the upcoming report has changed -200% over the past month to -$0.03. This represents no change from what the company reported a year ago. ChromaDex currently has a Zacks Rank of #3 (Hold).

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Precision BioSciences, Inc. (DTIL) : Free Stock Analysis Report

ChromaDex Corporation (CDXC) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.